Novartis records multi-million dollar loss on recent acquisition
The Swiss pharmaceutical company Novartis has to make a painful write-down of $800 million on a recently completed acquisition[1]. The acquisition in question was only finalized in August of this year, making the situation particularly noteworthy[2]. This development underscores the inherent risks in the pharmaceutical industry, where even carefully vetted investments can prove to be loss-making[2]. Experts point out that such setbacks are not uncommon, especially when acquiring startups without market-ready products[2]. The pharmaceutical industry is known for regularly operating with billions of dollars, with occasional losses in the millions considered part of the business risk[2]. Despite thorough due diligence, new therapies can fail even in late stages of development, leading to significant financial losses[2]. Sources:[1] ubernahme-flop-kostet-novartis-hunderte-millionen-766075 https://www.handelszeitung.ch/unternehmen/ubernahme-flop-kostet-novartis-hunderte-millionen-766075[2] Warum Novartis 800 Millionen Dollar auf eine Akquisition abschreiben muss, die erst im August abgeschlossen wurde https://www.handelszeitung.ch/unternehmen/ubernahme-flop-kostet-novartis-hunderte-millionen-766075
